RecruitingNot Applicable

CLABSI Prevention With Tissue Adhesive

Israel600 participantsStarted 2023-03-15

Plain-language summary

Our aim is to test the effect of tissue adhesive application at the Central-line exit-site on CLABSI rates in high-risk pediatric congenital heart disease patients.

Who can participate

Age range0 Days – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: All patients admitted to pediatric cardiac ICU (PCICU) defined as high-risk for CLABSI (any of): * young age\<1y \& Congenital Heart Surgery Mortality Category (STAT\\STS-EACTS) score 2-5 * Risk Adjustment for Congenital Heart Surgery (RACHS) category ≥3 * preoperative length-of-stay (LOS) \>7 days * preoperative ventilator support * presence of a genetic abnormality * extracorporeal membrane oxygenation (ECMO) support Exclusion Criteria: * Patients with on-going bacteremia * patients with pre-existing central-line or peripherally inserted central catheter (PICC) * parental refusal to participate.

What they're measuring

CLABSI rate

Timeframe: up to 1 year

Trial details

NCT IDNCT05721677

SponsorRabin Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03-15

Contact for this trial

Eran Shostak, MD

972-3-9253114 eransho@clalit.org.il

View on ClinicalTrials.gov More Central-line Associated Blood Stream Infections (CLABSI) trials